SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2024 financial and operating results after the market closes on Wednesday, August 7, 2024, and will host a conference call and […]
Category Archives: Pr Newswire
Pr Newswire
Ocuphire Pharma to Highlight APX3330 for Diabetic Retinopathy at Two Scientific Meetings in July
10
Jul
Jul
CEO to participate in ARVO SIG panel on oral medications for retinal diseases ZETA-1 Phase 2 clinical trial subset analysis to be presented during the ASRS 42nd Annual Scientific Meeting FARMINGTON HILLS, Mich., July 10, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule […]
GUELPH, ON, July 10, 2024 /PRNewswire/ — Recurrent Energy, a subsidiary of Canadian Solar Inc. (“Canadian Solar”) (NASDAQ: CSIQ) and a global developer, owner, and operator of solar and energy storage assets, announced today that it has signed a 10-year Power Purchase Agreement (PPA) with GKN Automotive, the global leader in drive systems. This agreement […]
Latest enhancements solidify platform’s status as the market’s world-class environment for AI-powered simulation-driven innovation TROY, Mich., July 10, 2024 /PRNewswire/ — Altair (Nasdaq: ALTR), a global leader in computational intelligence, announced the release of Altair® HyperWorks® 2024, the market’s leading platform for design and simulation. The latest release delivers significant advancements in artificial intelligence (AI)-powered engineering and […]
WUXI, China, July 10, 2024 /PRNewswire/ — Sineng Electric, a global leading PV+ESS solution provider, ranks No.4 worldwide in PV inverter shipments for 2023. The prestigious recognition from S&P Global Commodity Insights – the world’s foremost provider of credit ratings, benchmarks, analytics, and workflow solutions – underscores Sineng’s commitment to excellence and its industry leadership. Sineng […]
SEOUL, South Korea, July 10, 2024 /PRNewswire/ — AIRS Medical, a pioneering force in artificial intelligence (AI) and robotics for healthcare applications, today announced the completion of its Series C funding round, securing $20 million from seven institutional investors in Korea. The investment, led by BSK Investment and Shinyoung Securities, underscores confidence not only in […]
In the news release, DTGO partners with leading AI software company SenseTime to launch “DTLM”, a new trilingual LLM for Thai, Chinese, and English, issued 10-Jul-2024 by SenseTime over PR Newswire, we are advised by the company that the photo caption, should read “(From left to right): Mr. Jeff Shi, President of APAC of SenseTime; […]
Pr Newswire
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease
10
Jul
Jul
SPRING, Texas, July 09, 2024 (GLOBE NEWSWIRE) — Io Therapeutics, Inc., presented today results from studies done on the potential for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease (PD), and Alzheimer’s disease (AD), with its clinical stage experimental therapeutic RXR nuclear receptor agonist compound IRX4204. IRX4204 is a highly potent and highly selective, […]
Pr Newswire
Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results
10
Jul
Jul
Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) — Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, […]
Pr Newswire
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age
10
Jul
Jul
ZORYVE cream provides rapid relief, with efficacy, safety, and tolerability demonstrated up to 56 weeks of treatment ZORYVE cream rapidly and significantly reduces itch, the most bothersome symptom of atopic dermatitis (AD) Once-daily cream is for use anywhere on the body for any duration AD is the most common type of eczema, affecting approximately 9.6 […]